Why ‘miracle’ weight-loss drugs in India are set to get cheaper after March 20

The country’s anti-obesity market is headed for a pricing shake-up. A clutch of pharma companies is preparing to launch more affordable versions of blockbuster weight-loss medicines such as Wegovy and Ozempic.This could significantly alter who can access medical treatment for obesity in India. Until now, such drugs have remained largely confined to affluent urban patients and private clinics, because of their high monthly cost and the need for long-term use.These medicines belong to a class of drugs called GLP-1 receptor agonists. These are injectable medicines that mimic a natural gut hormone called GLP-1 (glucagon-like peptide-1). The hormone plays a role in regulating appetite and blood sugar. By acting on the brain’s appetite centres, slowing the emptying of the stomach and improving insulin response, GLP-1 drugs help people feel full sooner and eat less, while also improving blood sugar control in people with diabetes.Patent expiry and what it changesThe pricing reset follows the expiry of the patent on semaglutide, the key active ingredient in Wegovy and Ozempic, on March 20. The patent expiry marks the end of Novo Nordisk’s exclusive right to commercially sell semaglutide in India.From March 21, six to seven Indian drugmakers — including Sun Pharma, Zydus Lifesciences, Dr Reddy’s and Natco Pharma — are expected to enter the market with generic versions. In India’s pharmaceutical industry, such moments are known as “patent cliffs”.Patent cliffs typically trigger a rapid influx of generic manufacturers, because multiple companies launch competing versions of the same drug at the same time. This leads to intense price competition within months, as firms try to capture market share among doctors and patients.More companies are expected to join over the next few months. This is likely to drive prices down in a segment that has so far been dominated by expensive innovator brands.Until now, high monthly costs and the need for prolonged use have limited these therapies to a narrow group of patients. Doctors say a much larger pool of people with obesity and type 2 diabetes could medically benefit from such treatments, but have been unable to afford them for long enough to see sustained results.The rise of GLP-1 drugs: why they took off so fastOver the past few years, GLP-1 drugs have gone from being niche diabetes medicines to global blockbusters. Originally developed to treat type 2 diabetes, they gained traction after large clinical trials showed that patients also experienced significant weight loss.This has reshaped how obesity is medically viewed — not merely as a lifestyle issue, but as a chronic metabolic condition linked to hormones, insulin resistance and appetite regulation. Many endocrinologists now prescribe GLP-1 drugs to patients who struggle with both weight and blood sugar control, particularly when diet and exercise alone have not delivered sustained results.The World Health Organisation and global health bodies have repeatedly flagged obesity as a growing public health crisis, especially in urban populations with sedentary lifestyles and high-calorie diets. In India, doctors point to rising rates of obesity and pre-diabetes even among younger adults, driven by desk-bound work, ultra-processed foods and lack of physical activity.For patients, GLP-1 drugs offer a medical tool to break a cycle where weight gain worsens insulin resistance, and insulin resistance in turn makes weight loss harder. Many users report reduced hunger and fewer food cravings, making lifestyle changes easier to sustain.However, the surge in demand has also brought concerns. Doctors have cautioned against cosmetic or unsupervised use of these injections for quick weight loss. Side effects such as nausea, vomiting and gastrointestinal discomfort are common, especially in the early weeks. There are also concerns about long-term safety data in people using the drugs primarily for weight loss rather than diabetes, and about the tendency for weight to return once the medication is stopped.Medical bodies stress that GLP-1 drugs are not “miracle cures” and work best when combined with long-term lifestyle changes, including diet, physical activity and behavioural support.What business will this deliver?Analysts expect the nearly Rs 1,400 crore weight-loss market to double in a year. The rapid expansion reflects rising obesity and pre-diabetes in urban India, increasingly sedentary lifestyles, and growing acceptance of medical intervention for weight management rather than viewing obesity solely as a lifestyle issue.Overall, the antidiabetic therapy market grew over 15% in January, led by the rapid uptake of innovative therapies, including Eli Lilly’s Mounjaro, which clocked Rs 112 crore in sales, according to research firm Pharmarack. Mounjaro belongs to a newer class of drugs known as dual GLP-1/GIP agonists. These act on two gut hormone pathways to improve blood sugar control and promote weight loss, and are being increasingly prescribed for people with type 2 diabetes who also struggle with excess weight.“Lower-priced generics are expected to sharply widen access, with the market expected to grow 10-fold over the next few years as competition intensifies,’’ analysts told TOI. In India, lower-priced generics have historically transformed access to chronic therapies — from diabetes and heart disease to hepatitis C — by making long-term treatment financially viable for larger sections of the population.Pricing details are not available, but analysts expect generic versions of semaglutide to be priced roughly 50% cheaper — around Rs 3,500 to Rs 4,000 per month for the starting dose. Even at these levels, annual costs would still run into tens of thousands of rupees. This underlines that affordability remains relative in a country where most obesity treatments are not covered by health insurance and are paid for out of pocket.Innovators, price cuts and the generics challengeBlockbuster therapies — Wegovy and Mounjaro, marketed by Novo Nordisk and Eli Lilly respectively — were launched at “India-specific prices” last year, while the global bestseller Ozempic made its India debut in December. These India-specific prices were significantly lower than in the US and Europe, but still far higher than most standard diabetes medicines. This reflects the high cost of biologic drug manufacturing, specialised injection devices (pens) and cold-chain storage requirements.In November last year, Novo Nordisk slashed Wegovy’s price by 37%, bringing the starting dose down to Rs 10,000 per month. Despite the cut, long-term monthly therapy costs have remained out of reach for many patients, particularly because obesity treatment typically requires sustained use over many months or even years.Who stands to gainSeveral firms with a significant presence in chronic therapies are expected to be frontrunners. Chronic therapies are medicines taken long-term for conditions such as diabetes, heart disease and obesity, where patient adherence and affordability become critical for sustained outcomes.Sun Pharma’s MD Kirti Ganorkar told TOI: “As India’s largest pharmaceutical company with leadership in cardiometabolic therapies, we are committed to improving access to generic semaglutide across the country after the patent expiry. Sun Pharma plans to be in the market on day-one of the generic launch. We are well positioned across both indications, chronic weight management and type 2 diabetes. Our brands will be available in an easy-to-use prefilled pen format, and we will ensure sufficient supply to meet the demand in India.”Meanwhile, companies such as Cipla and Eris have entered into marketing tie-ups with MNCs and domestic partners. Such co-marketing arrangements allow firms to scale distribution and doctor outreach in specialised therapy areas like injectables, where training physicians and patients in correct device use is crucial.Companies are also investing in aggressive field force expansion ahead of the launch. Field force expansion refers to increasing the number of medical representatives who visit doctors to explain new therapies, dosing protocols and patient-selection criteria — a key driver of uptake in chronic injectable medicines.Neeraj Sharma, CEO and MD of OneSource Specialty Pharma, a contract development and manufacturing organisation, said: “We believe the entry of generic semaglutide will unlock significant latent demand, providing a strong boost to an already expanding market. With our diversified customer base and portfolio of 11 device platforms, we are well positioned to support this next phase of market expansion.”Contract development and manufacturing organisations (CDMOs) design and produce medicines and drug-delivery devices on behalf of pharmaceutical companies. They stand to benefit as multiple generic players enter the injectable obesity-drug segment, increasing demand for manufacturing capacity, devices and supply-chain infrastructure.